Your shopping cart is currently empty

Fosfenopril (Fosinoprilat) is a potent angiotensin-converting enzyme (ACE) inhibitor that mitigates lipopolysaccharide-induced inflammation in monocytes through the suppression of TLR4/NF-κB signaling pathways, and Fosfenopril is utilized in cardiovascular and anti-inflammatory research to investigate molecular mechanisms of ACE inhibition.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $90 | - | In Stock |
| Description | Fosfenopril (Fosinoprilat) is a potent angiotensin-converting enzyme (ACE) inhibitor that mitigates lipopolysaccharide-induced inflammation in monocytes through the suppression of TLR4/NF-κB signaling pathways, and Fosfenopril is utilized in cardiovascular and anti-inflammatory research to investigate molecular mechanisms of ACE inhibition. |
| In vitro | Fosfenopril (0-10 μM) treatment for 5 minutes can inhibit the LPS-induced increase in TLR4 expression [1]. Fosfenopril (0-10 μM) treatment for 1 hour can reduce the LPS-activated NF-κB expression level [1]. Fosfenopril also inhibits the expression of LPS-induced pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) [1]. |
| In vivo | Single intravenous injection of Fosfenopril (0.5 mg/kg bolus plus 0.1 mg/kg/min) can increase para-aminohippuric acid (PAH) clearance and glomerular filtration rate (GFR) in canines [3]. |
| Synonyms | SQ27519, SQ 27519, Fosinoprilic acid, Fosinoprilat |
| Molecular Weight | 435.49 |
| Formula | C23H34NO5P |
| Cas No. | 95399-71-6 |
| Smiles | C(CP(CCCCC1=CC=CC=C1)(=O)O)(=O)N2C[C@@H](C[C@H]2C(O)=O)C3CCCCC3 |
| Relative Density. | 1.238g/cm3 |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (183.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.58 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.